Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Gross Profit: 2022-2025

Historic Gross Profit for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$403.4 million.

  • Addex Therapeutics' Gross Profit fell 307994.34% to -$403.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$438.0 million, marking a year-over-year decrease of 58503.73%. This contributed to the annual value of $439,184 for FY2024, which is 69.22% down from last year.
  • Latest data reveals that Addex Therapeutics reported Gross Profit of -$403.4 million as of Q2 2025, which was down 1,068.86% from -$34.5 million recorded in Q1 2025.
  • Addex Therapeutics' Gross Profit's 5-year high stood at $695,668 during Q2 2023, with a 5-year trough of -$49.6 billion in Q1 2022.
  • Its 3-year average for Gross Profit is -$513.9 million, with a median of $35,902 in 2024.
  • As far as peak fluctuations go, Addex Therapeutics' Gross Profit soared by 535.26% in 2023, and later plummeted by 307,994.34% in 2025.
  • Over the past 4 years, Addex Therapeutics' Gross Profit (Quarterly) stood at $614,955 in 2022, then plummeted by 88.60% to $70,082 in 2023, then tumbled by 97.54% to $1,721 in 2024, then tumbled by 307,994.34% to -$403.4 million in 2025.
  • Its last three reported values are -$403.4 million in Q2 2025, -$34.5 million for Q1 2025, and $1,721 during Q4 2024.